Dr. McGuire is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1201 E Marshall St Room 11-210
Dept Of Im-Hematology/Oncology/Palliative Care
Richmond, VA 23298Phone+1 804-828-4642Fax+1 804-628-5920- Is this information wrong?
Education & Training
- National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1973 - 1976
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1971 - 1973
- Baylor College of MedicineClass of 1971
Certifications & Licensure
- VA State Medical License 2012 - 2026
- TX State Medical License 1971 - 2014
- MD State Medical License 1974 - 2013
- IL State Medical License 1979 - 1987
- CT State Medical License 1972 - 1979
- DC State Medical License 1976 - 1977
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Start of enrollment: 2000 Jul 01
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2001 Jan 01
Publications & Presentations
PubMed
- 2 citationsCommentary on "Enteral Lactoferrin Supplementation for Prevention of Sepsis and Necrotizing Enterocolitis in Preterm Infants".Lauren Young, William McGuire, Peter W Fowlie> ;Neonatology. 2021 Feb 9
- 7 citationsELFIN, the United Kingdom preterm lactoferrin trial: interpretation and future questions 1.Janet E. Berrington, William McGuire, Nicholas D. Embleton> ;Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire. 2021 Feb 1
- Validity and Utility of Experimental Animal Models in Perinatal Research.Verena Walsh, William McGuire> ;Neonatology. 2021 Jan 1
- Join now to see all
Press Mentions
- First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian CancerJuly 26th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: